Sign in
WithdrawnNo phase

Long-term Effects of WISE Program Improving Frailty Status and Quality of Life for Adolescents With CHD

Key facts

Who runs it
National Yang Ming Chiao Tung University
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
1 Jul 2023
Ended
30 Dec 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • with WISE (Walking Instruction based on Self-Efficacy)
  • without WISE (Walking Instruction based on Self-Efficacy)
Record updated
22 March 2024
Why it stopped
Based on our previous investigations, we've decided to construct a scale first.

Who can take part

Age
12 years to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Aged between 12-18 years old
  • Congenital heart disease diagnosed by a doctor before the age of 2
  • The American New York Heart Association (NYHA) classifies the cardiac function as I-III grades
  • Adolescents and their parents or guardians can communicate in Mandarin and Taiwanese and have normal cognitive abilities
  • Those who are willing to cooperate with the research and complete the consent form

Who cannot take part

  • Received a heart transplant within one year
  • Have undergone open-heart surgery within six months
  • The New York Heart Association (NYHA) classifies the cardiac function as class IV
  • Combined with other congenital diseases

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Most children with congenital heart disease (CHD) are expected to survive until adulthood. In addition to physical limitations, the growing adolescents with CHD are also challenged at the psychosocial domains. Previous studies have investigated the frailty of elderly, but the research on the intervention to the frailty of adolescents with CHD has been limited. The aims of this study will apply the Walking Instruction based on Self-Efficacy (WISE) program to examine the long-term effects of improving frailty state and quality of life for adolescents with CHD.

The 2 groups in the trial

  • Experimental - with WISETreatment being tested

    The experimental group will provide walking health education leaflets and exercise measurement wristbands for exercise monitoring, and will be given the intervention of the WISE program: three times a week, each time walking for at least 30 minutes, with a pace between 100-130 steps/ minutes, and then increase the number or time weekly according to personal ability.

    Treatment: with WISE (Walking Instruction based on Self-Efficacy)

  • Control - without WISEExisting treatment, for comparison

    The procedure of the control group will be the same as that of the experimental group, providing walking and health education leaflets and exercise measurement wristbands for exercise monitoring, but no intervention in the WISE program.

    Treatment: without WISE (Walking Instruction based on Self-Efficacy)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Long-term Effects of WISE Program Improving Frailty Status and Quality of Life for Adolescents With Congenital Heart Disease
Record updated
22 March 2024